stockrowRegencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
Follow RGC
Alert me
Regencell Bioscience Holdings Limited (RGC) Return on assets
Regencell Bioscience Holdings Limited's return on assets over the twelve months to 30 June 2026 was 0.00%. Over the past ten years it has ranged from −321.4% (fiscal 2019) to −38.3% (fiscal 2023); the current reading is higher than 50% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2026 | −114.3% | (63.75) |
| FY2025 | −50.5% | (9.65) |
| FY2024 | −40.9% | (2.53) |
| FY2023 | −38.3% | 42.79 |
| FY2022 | −81.1% | 234.24 |
| FY2021 | −315.4% | (100.80) |
| FY2020 | −214.6% | 106.86 |
| FY2019 | −321.4% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | 3.80% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited | 0.00% |
| ALVO Alvotech compare | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. compare | −1.64% |
| TRLV Trulieve Cannabis Corp. compare | −17.6% |
| PRGO Perrigo Company plc compare | −20.2% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −66.3% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −69.3% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)